Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern
November 14, 2022 16:41 ET
|
Interpace Biosciences, Inc.
Q3 Revenue of $8.2 million up 2% versus Prior YearQ3 Adjusted EBITDA PositiveCash and Cash Equivalents total $6.3 million as of September 30, 2022 PARSIPPANY, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE)...